Skip to content

Lung USG Vs chest auscultation as a marker of atropinisation in patients with acute organophosphate poisoning: A randomised controlled trial

Lung USG VS chest auscultation as a marker of atropinisation in patients with acute organophosphate poisoning - NIL

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2025/03/083499
Enrollment
40
Registered
2025-03-26
Start date
Unknown
Completion date
Unknown
Last updated
2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: T600- Toxic effect of organophosphate and carbamate insecticides

Interventions

Intervention1: LUNG USG: Using lung USG for diagnosing atropinisation in OP poisoning patient. starting dose is 2mg and every 5 minutes the dose shall be doubled till atropinisation. The route shall b

Sponsors

AIIMS,BHUBANESWAR
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: i. All patients above 18 years of age from either gender with history of acute organophosphate poisoning presenting within 24hours and its clinical toxidrome. ii. Patients who are willing to give informed consent and actively participate in the study.

Exclusion criteria

Exclusion criteria: i. Patients with any other poisoning other than organophosphorus compounds. ii. Patients with history of heart diseases or other causes of pulmonary oedema / lower respiratory tract infection or other pulmonary co-morbidities. iii. Patients requiring mechanical ventilation.

Design outcomes

Primary

MeasureTime frame
To compare the time and amount of atropine required for atropinisation in case of acute organophosphate poisoning on using lung USG vs chest auscultation as a marker of atropinisation.Timepoint: To compare the time and amount of atropine required for atropinisation in case of acute organophosphate poisoning on using lung USG vs chest auscultation as a marker of atropinisation.

Secondary

MeasureTime frame
1. To compare the patient outcome in terms of mortality/ ICU admission/ discharge. 2. To compare the development of intermediate syndrome in patients Timepoint: 20 days

Countries

India

Contacts

Public ContactDr Satyabrata Guru

AIIMS,Bhubaneswar

devanandv312@gmail.com09497729910

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026